GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (XMAD:ORY) » Definitions » EV-to-EBIT

Oryzon Genomics (XMAD:ORY) EV-to-EBIT : -54.38 (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Oryzon Genomics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oryzon Genomics's Enterprise Value is €128.00 Mil. Oryzon Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.35 Mil. Therefore, Oryzon Genomics's EV-to-EBIT for today is -54.38.

The historical rank and industry rank for Oryzon Genomics's EV-to-EBIT or its related term are showing as below:

XMAD:ORY' s EV-to-EBIT Range Over the Past 10 Years
Min: -312.95   Med: -17.22   Max: 685.91
Current: -54.38

During the past 10 years, the highest EV-to-EBIT of Oryzon Genomics was 685.91. The lowest was -312.95. And the median was -17.22.

XMAD:ORY's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 10.2 vs XMAD:ORY: -54.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Oryzon Genomics's Enterprise Value for the quarter that ended in Mar. 2024 was €97.12 Mil. Oryzon Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.35 Mil. Oryzon Genomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2.42%.


Oryzon Genomics EV-to-EBIT Historical Data

The historical data trend for Oryzon Genomics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics EV-to-EBIT Chart

Oryzon Genomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.97 -35.30 -18.92 -24.54 -27.27

Oryzon Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.79 -13.05 -23.63 -27.27 -41.26

Competitive Comparison of Oryzon Genomics's EV-to-EBIT

For the Biotechnology subindustry, Oryzon Genomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's EV-to-EBIT falls into.



Oryzon Genomics EV-to-EBIT Calculation

Oryzon Genomics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=128.004/-2.354
=-54.38

Oryzon Genomics's current Enterprise Value is €128.00 Mil.
Oryzon Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oryzon Genomics  (XMAD:ORY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Oryzon Genomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-2.354/97.1239196
=-2.42 %

Oryzon Genomics's Enterprise Value for the quarter that ended in Mar. 2024 was €97.12 Mil.
Oryzon Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oryzon Genomics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Oryzon Genomics (XMAD:ORY) Business Description

Traded in Other Exchanges
Address
Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics (XMAD:ORY) Headlines

No Headlines